May 7, 2012
In this interesting episode, host Dr. Tim Cripe (Nationwide Children`s) and co-hosts Dr Lionel Chow (Cincinnati Children`s), Dr Andy Kolb (AI DuPont), and Donna Ludwinski (Solving Kids` Cancer) quiz Dr Paul Sondel and Dr Ken DeSantes (both from University of Wisconsin – Madison) on NK cells and the implications of KIR/KIR-ligand mismatch (killer immunoglobulin-like receptor) with regard to immunotherapy treatment of neuroblastoma.
Delgado DC, Hank JA, Kolesar J, Lorentzen D, et al. Genotypes of NK cell KIR receptors, their ligands, and Fc? receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Res. 2010 Dec 1;70(23):9554-61. Epub 2010 Oct 8. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2999644/
.Venstrom JM, Zheng J, Noor N, Danis KE, et al. KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma. Clin Cancer Res. 2009 Dec 1;15(23):7330-4. Epub 2009 Nov 24. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2788079/
.Alderson KL, Sondel PM. Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity. J Biomed Biotechnol. 2011;2011:379123. Epub 2011 May 24. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3110303/
Please send questions and comments to TWiPO@solvingkidscancer.org